Evidence map›Paper›PMID 30832701›Full record

SynthesisBMC pharmacology & toxicology2019

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.

Dan Liu, Biao Jin, Wei Chen, Peng Yun

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pharmacology & toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dan LiuDepartment of Endocrinology, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People's Republic of China. liudan315@163.com.
Biao JinDepartment of Critical Care Medicine, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People's Republic of China.
Wei ChenDepartment of Critical Care Medicine, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People's Republic of China.
Peng YunDepartment of Endocrinology, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People's Republic of China.
First People's Hospital of Jingzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular outcomes associated with DPP-4 inhibitors versus non-DPP-4 inhibitor users.

methodsAll English publications that compared the use of DPP-4 inhibitors and that reported cardiovascular outcomes in patients with T2DM were searched using specific terms. Studies were included if they satisfied the following inclusion criteria: They were randomized trials or observation cohorts/registries comparing DPP-4 inhibitors use in patients with T2DM; The studies included a large sample size of participants; And they reported cardiovascular outcomes as their main endpoints. RevMan 5.3 was used to analyze the data, and odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results.

resultsA total number of 157,478 participants with T2DM were included. Seventy-six thousand and twenty six patients were assigned to the DPP-4 inhibitor group whereas 81,452 patients were assigned to the control group. Results of the current analysis showed that during a mean follow-up time period ranging from 52 to 152 weeks, the primary endpoint (cardiovascular death/non-fatal myocardial infarction (MI)/non-fatal stroke) was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: 0.86-1.04; P = 0.26). Cardiovascular death (OR: 1.00, 95% CI: 0.90-1.10; P = 0.93), stroke (OR: 1.03, 95% CI: 0.89-1.18; P = 0.72), MI (OR: 0.97, 95% CI: 0.88-1.07; P = 0.59), all-cause mortality (OR: 0.84, 95% CI: 0.59-1.18; P = 0.31), hospitalization for cardiovascular complications (OR: 1.02, 95% CI: 0.96-1.09; P = 0.45) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: 0.90-1.23; P = 0.55) were also similarly manifested in both groups.

conclusionThe current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsObservational Studies as TopicOdds RatioRandomized Controlled Trials as TopicDipeptidyl-Peptidase IV InhibitorsCardiovascular deathCardiovascular outcomesDipeptidyl peptidase 4 inhibitorsType 2 diabetes mellitus

Identifiers

PMID30832701
PMCPMC6399924
OpenAlexW2918566284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.